Profile data is unavailable for this security.
About the company
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
- Revenue in EUR (TTM)3.31bn
- Net income in EUR617.10m
- Incorporated1998
- Employees5.07k
- LocationIpsen SA65 Quai Georges GorseBOULOGNE-BILLANCOURT 92100FranceFRA
- Phone+33 158335000
- Fax+33 158335001
- Websitehttps://www.ipsen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | 2.66bn | 175.50m | 4.87bn | 8.97k | 27.80 | 2.39 | 11.69 | 1.83 | 0.6765 | 0.6765 | 10.23 | 7.87 | 0.6284 | 1.76 | 3.67 | 253,693.80 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 4.54 |
Orion Oyj | 1.19bn | 216.80m | 4.87bn | 3.63k | 22.28 | 5.44 | 18.46 | 4.09 | 1.55 | 1.55 | 8.49 | 6.34 | 0.8088 | 1.57 | 5.56 | 327,588.10 | 14.72 | 19.47 | 18.03 | 24.16 | 55.30 | 59.38 | 18.20 | 20.71 | 1.75 | 94.79 | 0.1835 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
DiaSorin SpA | -100.00bn | -100.00bn | 4.97bn | 3.28k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.14 | -- | 14.79 | -- | 67.40 | -- | 23.33 | -- | -- | -- | 23.89 | 9.98 | 16.38 | -22.53 | 11.49 | 21.76 | 5.29 |
Grifols SA | 6.59bn | 59.31m | 5.09bn | 23.74k | 92.04 | 0.9668 | 8.18 | 0.7723 | 0.0901 | 0.0901 | 9.80 | 8.58 | 0.3068 | 1.23 | 9.86 | 277,627.00 | 0.8408 | 2.39 | 1.06 | 3.04 | 37.84 | 40.26 | 2.74 | 7.54 | 1.29 | 1.56 | 0.5593 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
Zealand Pharma A/S | 45.97m | -94.38m | 5.72bn | 253.00 | -- | 24.98 | -- | 124.49 | -12.57 | -12.57 | 6.01 | 27.28 | 0.1948 | 4.16 | 289.88 | 1,354,889.00 | -39.99 | -42.74 | -46.30 | -50.24 | 87.39 | 96.13 | -205.30 | -464.66 | 6.23 | -- | 0.0696 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
BACHEM HOLDING AG | 589.98m | 114.31m | 6.48bn | 2.01k | 56.40 | 4.80 | 40.37 | 10.98 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
Croda International Plc | 1.98bn | 199.62m | 7.91bn | 5.85k | 39.68 | 2.88 | 22.72 | 4.00 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
Swedish Orphan Biovitrum AB (publ) | 1.93bn | 209.67m | 8.40bn | 1.79k | 36.79 | 2.73 | 17.20 | 4.36 | 7.40 | 7.40 | 68.65 | 99.68 | 0.3497 | 1.38 | 4.25 | -- | 3.81 | 5.93 | 5.20 | 7.60 | 77.58 | 77.41 | 10.88 | 16.61 | 0.4607 | 4.04 | 0.3769 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Qiagen NV | 1.82bn | 315.26m | 8.74bn | 5.97k | 27.93 | 2.48 | 17.31 | 4.82 | 1.41 | 1.41 | 8.12 | 15.89 | 0.3169 | 1.93 | 5.38 | 304,232.90 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Ipsen SA | 3.31bn | 617.10m | 9.15bn | 5.07k | 14.77 | 2.36 | 12.89 | 2.77 | 7.39 | 7.72 | 39.66 | 46.29 | 0.554 | 1.99 | 5.23 | -- | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.1106 | 19.87 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
Recordati Industria Chmc Frmctc SpA | 2.03bn | 375.37m | 10.82bn | 4.37k | 28.49 | 6.16 | 20.78 | 5.33 | 1.82 | 1.82 | 9.84 | 8.39 | 0.495 | 1.57 | 4.99 | 465,081.00 | 9.14 | 12.82 | 11.59 | 16.38 | 68.78 | 71.05 | 18.47 | 22.48 | 0.8599 | 11.85 | 0.5128 | 61.83 | 17.29 | 7.55 | -19.08 | 1.58 | 45.87 | 6.23 |
Eurofins Scientific SE | 6.51bn | 516.50m | 11.08bn | 61.80k | 22.00 | 2.17 | 9.78 | 1.70 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
Sandoz Group AG | -102.19bn | -102.19bn | 11.71bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
BioMerieux SA | 3.67bn | 357.60m | 11.98bn | 13.84k | 33.62 | 3.19 | 23.32 | 3.26 | 3.01 | 3.01 | 30.85 | 31.76 | 0.7036 | 1.97 | 5.00 | -- | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 19.01 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
Holder | Shares | % Held |
---|---|---|
Parvus Asset Management Europe Ltd.as of 27 Apr 2023 | 4.24m | 5.06% |
The Vanguard Group, Inc.as of 07 Mar 2024 | 1.21m | 1.45% |
Oddo BHF Asset Management SASas of 29 Feb 2024 | 859.68k | 1.03% |
Norges Bank Investment Managementas of 31 Dec 2023 | 857.79k | 1.02% |
BlackRock Fund Advisorsas of 07 Mar 2024 | 801.02k | 0.96% |
BlackRock Advisors (UK) Ltd.as of 07 Mar 2024 | 494.33k | 0.59% |
Black Creek Investment Management, Inc.as of 30 Sep 2023 | 463.57k | 0.55% |
Liontrust Investment Partners LLPas of 31 Jan 2024 | 338.36k | 0.40% |
Dimensional Fund Advisors LPas of 07 Mar 2024 | 307.35k | 0.37% |
Geode Capital Management LLCas of 20 Mar 2024 | 288.77k | 0.35% |